Glooko Raises $16.5 Million for Diabetes Management Platform
Using Glooko's Bluetooth-enabled MeterSync device, patients are able to sync data from blood glucose monitors with Apple or Android mobile devices.Diabetes management specialist Glooko announced that it has raised $16.5 million in Series B financing, which will be used to expand the company's FDA-cleared, Health Insurance Portability and Accountability Act (HIPAA)-compliant platform to include device data from insulin pumps and continuous glucose monitoring systems as well as integration of personalized predictive algorithms. The company's Web and mobile application is designed to improve health outcomes for people with diabetes, and the platform syncs with more 30 blood glucose meters as well as a number of major fitness and activity trackers, and supplies verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Using Glooko's Bluetooth-enabled MeterSync device, patients are already able to sync data from blood glucose monitors with their Apple or Android mobile device. Glooko's mobile app enables patients to track and manage aspects of their diabetes care, while the population management Web app and application programming interfaces (APIs) offer diabetes-centric analytics and supply reports, graphs and risk flags to health systems and payers.
"With the confluence and broad adoption of mobile and cloud technology, new government health care policy focused on value and outcomes, and the economics of health care moving toward incentives for keeping patients out of the hospital, both patients and their care providers are more able and incentivized to adopt technology to improve," Rick Altinger, CEO of Glooko, told eWEEK.